Overall, our study translates somewhat into a human cell biology setting and suggests that PARP-1 inhibition may be a therapeutic option in MLD, where marketed drugs such as Olaparib may be worthy of further investigation. Here, PARP1 is linked to metachromatic leukodystrophy.